Русский

Pharmaceutical Industry Information Portal

HomeTagsSotrovimab

All posts by tag

Sotrovimab

Sotrovimab, sold under the brand name Xevudy, is a human neutralizing monoclonal antibody with activity against severe acute respiratory syndrome coronavirus 2, known as SARS-CoV-2. It is under development by GlaxoSmithKline and Vir Biotechnology, Inc. Sotrovimab is designed to attach to the spike protein of SARS-CoV-2.  Read more

Newsletter

FDA limits use of GlaxoSmithKline and Vir’s COVID-19 antibody treatment in some geographic areas

Techno -
The United States Food and Drug Administration stated GlaxoSmithKline and Vir Biotech's COVID-19 antibody treatment should not be used in places with circulation...
World Pharma News

Xevudy (sotrovimab) granted marketing authorisation by the EC for the early treatment of COVID-19

Techno -
GlaxoSmithKline plc and Vir Biotechnology, Inc. announced that the European Commission (EC) has granted marketing authorisation to Xevudy (sotrovimab) for the early treatment of COVID-19....
Discovery and Development

COVID-19 dual-antibody therapies prevent emergence of drug resistance

Techno -
Administration of antibody therapies bypasses the body’s slower and sometimes less effective process of making its own antibodies.
spot_img

Expert Articles

spot_img

Information Internet project PharmProm.Net dedicated to the pharmaceutical industry in the world. It contains a contact base of organizations, enterprises, companies associated with the pharmaceutical market. The editorial staff of the PharmProm.Net portal offers cooperation in the field of information promotion and advertising in the pharmaceutical market.

Read our Russian-language online magazine

Categories